No correlation between MASLD and poor outcome of Atezolizumab‐Bevacizumab therapy in patients with advanced HCC.
Saved in:
| Title: | No correlation between MASLD and poor outcome of Atezolizumab‐Bevacizumab therapy in patients with advanced HCC. |
|---|---|
| Authors: | Copil, Francisca‐Dora1 (AUTHOR), Campani, Claudia2 (AUTHOR), Lequoy, Marie3 (AUTHOR), Sultanik, Philippe1 (AUTHOR), Blaise, Lorraine4 (AUTHOR), Wagner, Mathilde5 (AUTHOR), Ganne‐Carrié, Nathalie2,4 (AUTHOR), Ozenne, Violaine3 (AUTHOR), Thabut, Dominique1,6 (AUTHOR), Nault, Jean‐Charles2,4 (AUTHOR), Ratziu, Vlad1,6 (AUTHOR), Allaire, Manon1,2,7 (AUTHOR) manon.allaire@aphp.fr |
| Source: | Liver International. Apr2024, Vol. 44 Issue 4, p931-943. 13p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
